March 5, 2026
“Steady state” is one of those foundational pharmacokinetic terms that we use all the time — yet it can still feel abstract. We know it’s important. We calculate it routinely, and we reference it in dosing discussions. But what does it really mean in a practical sense?
Formally, steady state is defined as the point at which the rate of drug input equals the rate of drug elimination. In other words, the amount of drug entering the body over a given period is exactly balanced by the amount being cleared during that same period.
A helpful way to think about this is to imagine you deposit $20 into a bank account at the end of each pay period. However, at the same time, the bank removes 50% of the total balance as a “tax.” Importantly, the tax is calculated on the entire balance in the account and not just on that week’s $20 deposit.
At first, the account grows quickly. After the first deposit, 50% of the balance is removed, leaving $10. After the next deposit, the balance before tax is $30, so the tax is $15, leaving $15. The balance keeps increasing but by smaller and smaller amounts.
| Pay | Total Before Tax | Taxes (50%) | Cumulative Remaining |
|---|---|---|---|
| 20 | 0 | 10 | 10 |
| 20 | 30 | 15 | 15 |
| 20 | 35 | 17.5 | 17.5 |
| 20 | 37.5 | 18.8 | 18.8 |
| 20 | 38.8 | 19.4 | 19.4 |
| 20 | 39.4 | 19.7 | 19.7 |
| 20 | 39.7 | 19.8 | 19.8 |
| 20 | 39.8 | 19.9 | 19.9 |
| 20 | 39.9 | 20.0 | 20.0 |
| 20 | 40.0 | 20.0 | 20.0 |
| 20 | 40.0 | 20.0 | 20.0 |
Why? Because the tax is proportional to the total balance. As the account grows, the tax grows too. Eventually, the tax reaches $20, which is exactly equal to the deposit. At that point, the balance stabilizes at $40. You are still depositing $20 each period, and the bank is still removing 50%, but the total amount in the account no longer changes.
That’s steady state.
In pharmacokinetic terms:
- The $20 deposit represents each dose.
- The 50% tax represents first-order elimination (a constant fraction removed per unit time).
- The account balance represents the total amount of drug in the body.
And thankfully, this is not how taxes work in real life! You’re taxed on what you earn, not on your entire bank balance each week. Your body, however, is less generous. Drug elimination depends on the total amount in the system, not just the most recent “deposit.”
PK parameters associated with steady state
How do we calculate steady state?
There are several pharmacokinetic parameters that are particularly useful when a drug has reached steady state. These parameters are not inherently more important than others. But they become especially informative because steady state represents a unique condition: the rate of drug input equals the rate of drug elimination.
One of the most important steady-state parameters is the average plasma concentration at steady state, or Css. This parameter can be calculated based on the steady state definition, where the rate of input is equal to the rate of elimination.
Rate of input = \frac{F \times \text{Dose}}{\tau}
(where τ is the dosing interval, and F is the bioavailability of the drug)
Rate of elimination = CL*Cp
At steady state, Cp becomes Css, and rate of input equals rate of elimination.
Equating the equations above:
Rate of input = Rate of elimination, so: Rate of input = \frac{F \times \text{Dose}}{\tau} = CL * Css
Solving for Css:
We also know the fundamental relationship between dose, clearance, and bioavailability:
Rearranging and substituting into the earlier Css equation gives:
This is an extremely useful and elegant result:
- The average steady-state concentration is simply the total exposure over one dosing interval divided by the length of that dosing interval.
- Even though drug concentrations rise and fall during each dosing interval at steady state, the average concentration remains constant.
Importantly, Css is controlled only by:
- Dose
- Dosing interval (τ)
- Clearance (CL)
Assuming that clearance is not altered, steady-state concentrations can be adjusted by modifying the dose or the dosing interval. Lower doses or longer intervals reduce Css. Higher doses or shorter intervals increase Css.
Intravenous infusion
For continuous intravenous infusion, the situation becomes even simpler. You can directly calculate the Css at steady state using the following equation:
C_{ss} = \frac{R_0}{CL} where R0 is the infusion rate.
This shows a direct proportional relationship: If you double the infusion rate, you double Css (assuming clearance remains constant).
A useful shortcut: single-dose AUC
There is also a practical shortcut that connects single-dose data to steady state.
At steady state:
Because of this equality, if you calculate AUC0–∞ after a single dose, you can predict steady-state concentrations for any dosing interval using:
If dose proportionality holds, this approach can also be extended to different dose levels.
Time to reach steady state
Calculate steady state from half-life
The time required to reach steady state is determined entirely by the drug’s elimination half-life.
Because elimination is first-order for most drugs, the approach to steady state follows a predictable pattern:
- After 1 half-life → 50% of steady state
- After 2 half-lives → 75% of steady state
- After 3 half-lives → 87.5%
- After 4 half-lives → 93.75%
- After 5 half-lives → ~97%
For this reason, we use a simple rule of thumb:
- Steady state is effectively achieved after about 4–5 half-lives.
Importantly, the time to reach steady state depends only on half-life and not on the dose. Increasing the dose will increase the steady-state concentration, but it will not make steady state occur any faster.
If a drug has a half-life of one day, steady state will be reached in about 4–5 days. If the half-life is one week, steady state will take about 4–5 weeks.
Using a loading dose to reach target concentrations faster
For drugs with long half-lives, waiting 4–5 half-lives may be clinically impractical. In these situations, a loading dose can be used to achieve the target steady-state concentration more quickly.
For example, suppose:
- A 30 mg once-daily dose produces a Css of 10 ng/mL
- The drug takes 10 days (≈5 half-lives) to reach steady state
Assuming dose proportionality, doubling the dose to 60 mg daily would eventually produce a Css of 20 ng/mL — but it would still take 10 days to get there.
Now consider what happens after a single 60 mg dose. After one half-life, 50% of that eventual steady state is achieved. If the projected steady state for 60 mg daily is 20 ng/mL, then after one half-life the concentration would be approximately:
20 ng/mL × 50% = 10 ng/mL
That is exactly the target concentration we wanted.
So instead of waiting 10 days, we could:
- Give a one-time 60 mg loading dose
- Then continue with 30 mg daily as the maintenance dose
This approach allows the patient to reach the desired concentration within about 1–2 days rather than waiting through multiple half-lives.
The larger first dose is the loading dose, and the smaller ongoing dose is the maintenance dose. The maintenance dose is the amount required to maintain steady state once it has been achieved.
Connecting back to the “50% tax” analogy
Notice how this ties directly back to the 50% “tax” in our earlier bank account example. Removing 50% of the total balance each period is mathematically identical to a half-life. A half-life is simply the time required for 50% of the drug in the body to be eliminated.
In this example, each pay period represents one half-life. Every period, half of the total amount in the account is removed. That’s why the system approaches steady state in a very predictable way.
By about 4–5 half-lives, the balance is so close to $40 that we consider it to have effectively reached steady state.
This is exactly what happens in the body. If a drug has a half-life of one day, steady state will be reached in about 4–5 days. If the half-life is one week, steady state will take about 4–5 weeks.
The time to steady state depends only on the half-life and not on the dose.
- Half-life determines how fast you get there.
- Clearance and dose determine what drug exposure level you get to.
Final thoughts
In summary, steady-state pharmacokinetics are especially important for drugs that are administered chronically. Most maintenance therapies, whether taken once daily, twice daily, or by continuous infusion, are designed with steady state in mind.
At its core, the concept is simpler than it may first appear: steady state occurs when the rate of drug input equals the rate of drug elimination. Once you understand that balance, many of the related principles (Css, time to steady state, half-life, loading doses) begin to fall into place logically.
How to calculate time to steady state and Css from a single dose in Phoenix WinNonlin®
If the appropriate assumptions hold (linear kinetics, dose proportionality, time-invariant clearance), steady-state concentrations and time to steady state can be predicted directly from single-dose data.
Using a Phoenix® NCA object, you can calculate key parameters such as AUC₀–∞, clearance, and half-life from a single-dose study. You can define an additional parameters to predict:
Css for different dosing intervals (τ) using the formula C_{ss}=\frac{AUC}{\tau}
Time to steady state can be estimated from the elimination half-life (approximately 4–5 half-lives).
This approach allows you to simulate steady-state exposure without conducting a multiple-dose study, provided the assumptions of linear pharmacokinetics are met.
If you have an account at https://my.certara.net, click here to access the full article and download a Phoenix project example that demonstrates these calculations within an NCA object.
If you would like to explore this topic in more depth, steady-state concepts and their practical application in Phoenix are covered in Certara University’s Phoenix WinNonlin (Part 1) NCA Certification Course (Code 122).
Access your free PK/PD resource
Authored by Prof. Johan Gabrielsson, this trusted eBook provides comprehensive insights into pharmacokinetics and pharmacodynamics. Simply register with your professional or academic email to access the standard book “Pharmacokinetic and Pharmacodynamic Data Analysis” – completely free!
We’re committed to delivering content that truly matters to you most so Phoenix Newsletters are your go-to monthly resource for the latest and greatest Phoenix insights.
This blog was originally published in June 2010 and has been updated for accuracy.
Author

Ana Henry
Executive Director, Training & Certara UniversityAna leads the Certara University team in providing modeling and simulation for new drug development through education, skills, and expertise in the global healthcare industry. Ana has more than 20 years experience in a variety of roles in the industry. She has extensive experience in pharmaceutical training, software demonstration, software support, and product management, Ana is also an adjunct faculty member at Skaggs College of Pharmacy and Pharmaceutical Sciences at the University of Colorado.
